425 related articles for article (PubMed ID: 20950191)
1. Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Lee H; Ko KS; Song JH; Peck KR
Microb Drug Resist; 2011 Mar; 17(1):37-45. PubMed ID: 20950191
[TBL] [Abstract][Full Text] [Related]
2. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
3. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
Christiansen KJ; Ip M; Ker HB; Mendoza M; Hsu L; Kiratisin P; Chongthaleong A; Redjeki IS; Quintana A; Flamm R; Garcia J; Cassettari M; Cooper D; Okolo P; Morrissey I
Int J Antimicrob Agents; 2010 Dec; 36(6):501-6. PubMed ID: 20869212
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study.
Gales AC; Azevedo HD; Cereda RF; Girardello R; Xavier DE;
Braz J Infect Dis; 2011; 15(6):513-20. PubMed ID: 22218508
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
[TBL] [Abstract][Full Text] [Related]
8. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
9. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Dong SX; Wang JT; Chang SC
J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Fritsche TR; Stilwell MG; Jones RN
Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
13. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Castanheira M; Jones RN; Livermore DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
18. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Gimeno C; Cantón R; García A; Gobernado M;
Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.
Jacquier H; Le Monnier A; Carbonnelle E; Corvec S; Illiaquer M; Bille E; Zahar JR; Jauréguy F; Fihman V; Tankovic J; Cattoir V;
Microb Drug Resist; 2012 Aug; 18(4):396-401. PubMed ID: 22335615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]